SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Ella Fitzgerald

PatientElla Fitzgerald
Date of birth1956-04-25
IdentifiersMRN HR-ML029-SYN; SSN (made up) 000-29-3640
Document date2026-10-26
AuthorOdessa Whitlow, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-and-a-half-month review: A1c, lipids, walking distance, the revascularization decision, foot and eye follow-up. [S]

History of Present Illness

Ms. Fitzgerald returns eleven weeks after her three-month visit. She stepped up to semaglutide 0.5 mg weekly in September; she had mild nausea for the first two weeks, which passed, and she has lost 1.5 kg. Her glucose monitor shows time in range 74% and time below 70 mg/dL 0.6%, with no reading below 54 mg/dL. She finished the supervised exercise program and walks most days; she can now walk about five blocks before calf pain, and only climbing slows her. She has no rest pain and no sores. She has had five right-eye injections and the interval is now eight weeks. The podiatrist saw her in September. She has had no bleeding. Her mammogram in July was normal, and the bone density scan is booked between tours. She feels ready for her winter tour. [S]

ElementDetail
GlucoseTime in range 74%; time below 70 mg/dL 0.6%; none below 54
Semaglutide0.5 mg weekly since September; nausea passed
WalkingAbout five blocks; no rest pain
Eye treatmentFive injections; now every eight weeks

Review of Systems

SystemResultFinding
CardiovascularPositiveCalf pain only after about five blocks or on hills; no chest pain
GastrointestinalNegativeNausea resolved; no vomiting or abdominal pain
EyesNegativeRight-eye vision clearer
IntegumentaryNegativeNo foot sores

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with breakfast and the evening mealOral route2016-03-01activeS
Glipizide 10 mg oral tablet, one tablet by mouth twice daily before mealsOne tablet by mouth twice daily before breakfast and the evening mealOral route2021-09-01 to 2026-05-11completedS
Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime30 units at bedtimeSubcutaneous route2023-04-01 to 2026-05-11completedS
Insulin glargine 100 units/mL pen, 24 units under the skin each morning24 units each morning, at the same clock time on tour, with written time-zone adjustmentsSubcutaneous route2026-05-11activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2025-06-02 to 2026-05-11completedS
Atorvastatin 80 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-05-11activeS
Aspirin 81 mg delayed-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2025-06-02activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2025-06-02activeS
Empagliflozin 10 mg oral tablet, one tablet by mouth each morningOne tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgeryOral route2026-05-11activeS
Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucoseOne spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911Nasal route2026-05-11activeS
Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mgOne tablet by mouth twice daily, with aspirin 81 mg once dailyOral route2026-05-26activeS
Semaglutide 0.25 mg under the skin once weekly for four weeks0.25 mg once weekly on the same day each week for four weeksSubcutaneous route2026-08-10 to 2026-09-07completedS
Semaglutide 0.5 mg under the skin once weekly0.5 mg once weekly on the same day each weekSubcutaneous route2026-09-07activeS
Ezetimibe 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-08-10activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-26Body height165cmS
2026-10-26Body weight80.6kgS
2026-10-26Body mass index (BMI) [Ratio]29.6kg/m2S
2026-10-26Systolic blood pressure120mm[Hg]S
2026-10-26Diastolic blood pressure68mm[Hg]S
2026-10-26Heart rate60/minS
2026-10-26Respiratory rate16/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-26Hemoglobin A1c/Hemoglobin.total in Blood7.1%Below 5.7% is normal; her individualized goal is below 7.5%HighS
2026-10-26Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-10-26Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.59-1.04 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M65mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-26Cholesterol [Mass/volume] in Serum or Plasma114mg/dL<=199 mg/dLNormalS
2026-10-26Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation48mg/dLHer goal with coronary and peripheral artery disease is below 55 mg/dLNormalS
2026-10-26Cholesterol in HDL [Mass/volume] in Serum or Plasma47mg/dL>=50 mg/dLLowS
2026-10-26Triglyceride [Mass/volume] in Serum or Plasma96mg/dL<=149 mg/dLNormalS
2026-10-26Visual acuity best corrected Right eye by ETDRS eye chart75{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50LowS
2026-10-26Visual acuity best corrected Left eye by ETDRS eye chart81{letters}85 letters is about 20/20; 80 about 20/25; 65 about 20/50NormalS

Physical Exam

Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 80.6 kg, BMI 29.6; blood pressure 120/68, pulse 60
FeetSkin intact; minimal callus; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; feet warm
EyesBest-corrected acuity 75 letters right and 81 letters left

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complicationsactiveconfirmed E11.51S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic.
Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problemsactiveconfirmed E11.3311S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display.
Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgeryactiveconfirmed I25.10S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryHemoglobin A1cEvery three months when not at goal or after a change; every six months at goalCompleted today7.1%, at goal; every six months from now
Medication safetyContinuous glucose monitor review: time in range and time below rangeEvery visitCompleted todayTime in range 74%; time below 70 mg/dL 0.6%
Medication safetyHypoglycemia events, show-day plan, and glucagonEvery visitCompleted todayNo level 2 or 3 lows since intake
Medication safetyEmpagliflozin safety: genital infection, volume, and sick-day rulesAt the start and every visitCompleted todayNo side effects
LaboratoryCreatinine, eGFR, and potassiumWithin three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban reviewCompleted todayCreatinine 0.94 mg/dL, eGFR 65, potassium 4.5, sodium 139 mmol/L
LaboratoryUrine albumin-creatinine ratioYearlyUp to date18 mg/g at intake; repeat at the next yearly check
LaboratoryLipid panel4 to 12 weeks after a statin or other lipid-lowering change, then yearlyCompleted todayLDL 48 mg/dL eleven weeks after ezetimibe was added, at goal
ExaminationFoot inspection, protective sensation, and pulsesEvery visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six monthsCompleted todayNo ulcer; podiatry in September; next in December
ImagingAnkle-brachial and toe-brachial indicesAt diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptomsDueWith arterial duplex at the vascular review next month, six months after the consultation
ExaminationWalking distance and claudication symptomsEvery visitCompleted todayAbout five blocks; claudication no longer limits her
Self-managementSupervised exercise therapyThree times a week for twelve weeksCompleted todayProgram completed; walking most days
ImagingRetinal examination and visual acuityWith each retina-clinic treatment while macular edema is treated; at least yearly in both eyesCompleted todayAcuity 75 letters right and 81 left; five injections
ExaminationBlood pressureEvery visitCompleted today120/68 mmHg
ExaminationWeight and BMIEvery visitCompleted today80.6 kg, down 3.4 kg since intake
Medication safetyBleeding on rivaroxaban and aspirinAt the start and every visitCompleted todayNo bleeding
Medication safetySemaglutide tolerance: nausea, appetite, and dose stepAt the start and each dose stepCompleted today0.5 mg weekly; nausea passed
Self-managementAccess and equity: tour-date scheduling, video visits, large print, drug costsEvery visitCompleted todayVideo visit planned during the winter tour; prescriptions synchronized for travel

Goal progress:

Immunizations given today: Influenza vaccine, high-dose, 2026-2027 season; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026); Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025)

Follow-up: Vascular review with ankle-brachial index and duplex next month. Podiatry in December. Retina clinic every eight weeks. Video visit during the winter tour; in-person review in three months with A1c. [S]